Paper7004534
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.
Sullivan KM and 8 others. Blood, 1981. Cited by 895 papers, by iCite.
Cite this record
ConductScience Library. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Papers, record 7004534. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7004534
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antilymphocyte Serum | Major topic |
| Azathioprine | Major topic |
| Graft vs Host Reaction | Major topic |
| Prednisone | Major topic |
| Bone Marrow Transplantation | |
| Chronic Disease | |
| Drug Therapy, Combination | |
| Follow-Up Studies | |
| Humans | |
| Transplantation, Homologous |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 15704 | NCI NIH HHS | United States | P01CA015704 | PubMed and NIH | NIH RePORTER |
| CA 18029 | NCI NIH HHS | United States | P01CA018029 | PubMed and NIH | NIH RePORTER |
| CA 18221 | NCI NIH HHS | United States | P01CA018221 | PubMed and NIH | NIH RePORTER |
| P30CA015704 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02701517 | Cyclosporine Plus Methotrexate or Alemtuzumab | Background |
Source ClinicalTrials.gov
Cited by216
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 895 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42931992 | Post-transplant monitoring of NGS-based measurable residual disease and donor chimerism as a prognostic tool in older patients with AML/MDS. | Blood Res | 2026 | https://conductscience.org/library/papers/42931992 | PubMed |
| 42401707 | CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/42401707 | PubMed |
| 42150590 | Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial. | Lancet Haematol | 2026 | https://conductscience.org/library/papers/42150590 | PubMed |
| 42037753 | Steroid-Refractory Chronic Graft-Versus-Host Disease-Associated Isolated Myositis Successfully Treated With Ruxolitinib: A Case Report. | EJHaem | 2026 | https://conductscience.org/library/papers/42037753 | PubMed |
| 41846916 | Evaluation of cyclophosphamide for steroid-refractory hepatic acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. | Front Immunol | 2026 | https://conductscience.org/library/papers/41846916 | PubMed |
| 41046057 | Umbilical Cord Blood Transplantation Provides an Alternative for Patients With Chronic Granulomatous Disease Lacking HLA-Matched Donors: A PIDTC Report. | Transplant Cell Ther | 2026 | https://conductscience.org/library/papers/41046057 | PubMed |
| 40236695 | Case Report: Diagnosis and successful treatment of a rare case of steroid-refractory chronic graft-vs-host disease-related serositis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40236695 | PubMed |
| 40175657 | Influence of pre-transplant estimated glomerular filtration rate (eGFR) on clinical outcomes after allogeneic hematopoietic cell transplantation. | Bone Marrow Transplant | 2025 | https://conductscience.org/library/papers/40175657 | PubMed |
| 38776400 | Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis. | Blood Adv | 2024 | https://conductscience.org/library/papers/38776400 | PubMed |
| 38534941 | Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. | Curr Oncol | 2024 | https://conductscience.org/library/papers/38534941 | PubMed |
| 37906445 | The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation. | Expert Rev Hematol | 2023 | https://conductscience.org/library/papers/37906445 | PubMed |
| 37844687 | Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. | Transplant Cell Ther | 2024 | https://conductscience.org/library/papers/37844687 | PubMed |
| 37562003 | Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. | Blood | 2023 | https://conductscience.org/library/papers/37562003 | PubMed |
| 37089776 | Association Between Candidemia and Noninfectious Interstitial Pneumonia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. | Open Forum Infect Dis | 2023 | https://conductscience.org/library/papers/37089776 | PubMed |
| 36979928 | Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation. | Biomedicines | 2023 | https://conductscience.org/library/papers/36979928 | PubMed |
| 36779595 | Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. | Haematologica | 2023 | https://conductscience.org/library/papers/36779595 | PubMed |
| 36572728 | Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation. | Bone Marrow Transplant | 2023 | https://conductscience.org/library/papers/36572728 | PubMed |
| 36450828 | First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens. | Bone Marrow Transplant | 2023 | https://conductscience.org/library/papers/36450828 | PubMed |
| 36446899 | Steroid-free first line treatment of moderate and severe chronic GVHD: a survey from the Transplant Complications Working Party of the EBMT. | Bone Marrow Transplant | 2023 | https://conductscience.org/library/papers/36446899 | PubMed |
| 36195679 | Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil. | Ann Hematol | 2022 | https://conductscience.org/library/papers/36195679 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7004534
GET https://conductscience.org/api/papers/v1/7004534/cited_by?page=2